Genflow Biosciences Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Eric Leire
Chief executive officer
UK£215.8k
Total compensation
| CEO salary percentage | 100.00% |
| CEO tenure | 4.8yrs |
| CEO ownership | 33.3% |
| Management average tenure | no data |
| Board average tenure | 3.6yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | -UK£2m |
| Mar 31 2025 | n/a | n/a | -UK£2m |
| Dec 31 2024 | UK£216k | UK£216k | -UK£2m |
| Sep 30 2024 | n/a | n/a | -UK£2m |
| Jun 30 2024 | n/a | n/a | -UK£2m |
| Mar 31 2024 | n/a | n/a | -UK£2m |
| Dec 31 2023 | UK£232k | UK£232k | -UK£2m |
| Sep 30 2023 | n/a | n/a | -UK£2m |
| Jun 30 2023 | n/a | n/a | -UK£1m |
| Mar 31 2023 | n/a | n/a | -UK£1m |
| Dec 31 2022 | UK£235k | UK£235k | -UK£1m |
| Jun 30 2022 | n/a | n/a | -UK£1m |
| Mar 31 2022 | n/a | n/a | -UK£1m |
| Dec 31 2021 | UK£148k | UK£148k | -UK£1m |
| Mar 31 2021 | n/a | n/a | -UK£651k |
Compensation vs Market: Eric's total compensation ($USD290.04K) is below average for companies of similar size in the US market ($USD586.75K).
Compensation vs Earnings: Eric's compensation has been consistent with company performance over the past year.
CEO
Eric Leire (67 yo)
Dr. Eric Patterson Jean Leire, M.D., MBA, was an Independent Director at PHAXIAM Therapeutics S.A. since 2023 until 2024. He serves as Founder and Chief Executive Officer at Genflow Biosciences plc. and se...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 4.8yrs | UK£215.79k | 33.31% $ 4.1m | |
| Independent Non-Executive Director | 3.6yrs | UK£27.50k | 0.22% $ 27.4k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Executive Chairperson of the Board | 3.6yrs | UK£27.50k | 0.16% $ 19.9k | |
| Independent Non-Executive Director | 4.6yrs | UK£28.15k | 0.26% $ 31.6k | |
| Independent Non-Executive Director | 4yrs | UK£28.15k | 0.24% $ 29.4k | |
| Chairman of Scientific Advisory Board | 2.7yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 2.7yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.7yrs | no data | no data |
Experienced Board: GENF.F's board of directors are considered experienced (3.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/02 11:16 |
| End of Day Share Price | 2025/12/26 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Genflow Biosciences plc is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.